Chronic myeloid leukemia: Diagnosis and treatment

Alfonso Quintás-Cardama, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

Chronic myeloid leukemia (CML) has become a model in research and management among malignant disorders. Since the discovery of the presence of a unique and constant chromosomal abnormality slightly more than 40 years ago, substantial progress has been made in the understanding of the biology of the disease. This progress has translated into significant improvement in the long-term prognosis of patients with this disease. This change came first with the use of stem cell transplantation and interferon alfa, but recently it has opened the era of melecularly targeted therapies, imatinib, a potent and selective tyrosine kinase inhibitor, may be the best example of our attempts to Identify molecular abnormalities and develop drugs directed specifically at them. Furthermore, the understanding of at least some of the mechanisms of resistance to imatinib has led to rapid development of new agents that may overcome this resistance. The outlook today for patients with CML is much brighter than just a few years ago. It is our hope that this fascinating journey in CML can be replicated in other malignancies. In this article, we review our current understanding of this disease.

Original languageEnglish (US)
Pages (from-to)973-988
Number of pages16
JournalMayo Clinic Proceedings
Volume81
Issue number7
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem Cell Transplantation
Interferon-alpha
Chromosome Aberrations
Protein-Tyrosine Kinases
Therapeutics
Research
Pharmaceutical Preparations
Neoplasms
Imatinib Mesylate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chronic myeloid leukemia : Diagnosis and treatment. / Quintás-Cardama, Alfonso; Cortes, Jorge E.

In: Mayo Clinic Proceedings, Vol. 81, No. 7, 07.2006, p. 973-988.

Research output: Contribution to journalArticle

Quintás-Cardama, Alfonso ; Cortes, Jorge E. / Chronic myeloid leukemia : Diagnosis and treatment. In: Mayo Clinic Proceedings. 2006 ; Vol. 81, No. 7. pp. 973-988.
@article{6153afc34ba04044b48a4f3f3a270ecf,
title = "Chronic myeloid leukemia: Diagnosis and treatment",
abstract = "Chronic myeloid leukemia (CML) has become a model in research and management among malignant disorders. Since the discovery of the presence of a unique and constant chromosomal abnormality slightly more than 40 years ago, substantial progress has been made in the understanding of the biology of the disease. This progress has translated into significant improvement in the long-term prognosis of patients with this disease. This change came first with the use of stem cell transplantation and interferon alfa, but recently it has opened the era of melecularly targeted therapies, imatinib, a potent and selective tyrosine kinase inhibitor, may be the best example of our attempts to Identify molecular abnormalities and develop drugs directed specifically at them. Furthermore, the understanding of at least some of the mechanisms of resistance to imatinib has led to rapid development of new agents that may overcome this resistance. The outlook today for patients with CML is much brighter than just a few years ago. It is our hope that this fascinating journey in CML can be replicated in other malignancies. In this article, we review our current understanding of this disease.",
author = "Alfonso Quint{\'a}s-Cardama and Cortes, {Jorge E.}",
year = "2006",
month = "7",
doi = "10.4065/81.7.973",
language = "English (US)",
volume = "81",
pages = "973--988",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Chronic myeloid leukemia

T2 - Diagnosis and treatment

AU - Quintás-Cardama, Alfonso

AU - Cortes, Jorge E.

PY - 2006/7

Y1 - 2006/7

N2 - Chronic myeloid leukemia (CML) has become a model in research and management among malignant disorders. Since the discovery of the presence of a unique and constant chromosomal abnormality slightly more than 40 years ago, substantial progress has been made in the understanding of the biology of the disease. This progress has translated into significant improvement in the long-term prognosis of patients with this disease. This change came first with the use of stem cell transplantation and interferon alfa, but recently it has opened the era of melecularly targeted therapies, imatinib, a potent and selective tyrosine kinase inhibitor, may be the best example of our attempts to Identify molecular abnormalities and develop drugs directed specifically at them. Furthermore, the understanding of at least some of the mechanisms of resistance to imatinib has led to rapid development of new agents that may overcome this resistance. The outlook today for patients with CML is much brighter than just a few years ago. It is our hope that this fascinating journey in CML can be replicated in other malignancies. In this article, we review our current understanding of this disease.

AB - Chronic myeloid leukemia (CML) has become a model in research and management among malignant disorders. Since the discovery of the presence of a unique and constant chromosomal abnormality slightly more than 40 years ago, substantial progress has been made in the understanding of the biology of the disease. This progress has translated into significant improvement in the long-term prognosis of patients with this disease. This change came first with the use of stem cell transplantation and interferon alfa, but recently it has opened the era of melecularly targeted therapies, imatinib, a potent and selective tyrosine kinase inhibitor, may be the best example of our attempts to Identify molecular abnormalities and develop drugs directed specifically at them. Furthermore, the understanding of at least some of the mechanisms of resistance to imatinib has led to rapid development of new agents that may overcome this resistance. The outlook today for patients with CML is much brighter than just a few years ago. It is our hope that this fascinating journey in CML can be replicated in other malignancies. In this article, we review our current understanding of this disease.

UR - http://www.scopus.com/inward/record.url?scp=33745592518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745592518&partnerID=8YFLogxK

U2 - 10.4065/81.7.973

DO - 10.4065/81.7.973

M3 - Article

C2 - 16835977

AN - SCOPUS:33745592518

VL - 81

SP - 973

EP - 988

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -